The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Genomic and immune signatures associated with resistance in patients with myeloma treated with D-KRd
Although treatment regimens consisting of anti-CD38 monoclonal antibodies, proteasome inhibitors and immunomodulatory drugs (IMiDs) have significantly improved the outcomes of patients with multiple myeloma, with measurable residual disease (MRD)-negativity rates of over 70%, many still experience disease progression. Francesco Maura, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, gives an overview of the findings of a study using whole-genome sequencing (WGS) and single-cell RNA-sequencing (scRNA-seq) to define the genomic and immune microenvironment signatures associated with resistance in patients with multiple myeloma treated with daratumumab, carfilzomib, lenalidomide and dexamethasone (D-KRd). It was shown that resistance is due to a complex interplay between tumor cells and the immune microenvironment. In addition, the study identified distinct genomic lesions associated with distinct microenvironment signatures, and distinct cell populations playing a role in response to therapy. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
